Secondary actigraphy analysis of the phase 2 ELEVATE-2 RCT in PAH (100 of 108 analysed): rodatristat ethyl reduced peak 5-minute steps (-49), daily steps (-656) and moderate activity time (-17.3 min/day) at week 24 vs placebo.
RCTn = 108
Lachant et al. Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial